In this episode, Shaji Kumar, MD, editor-in-chief of The Hematologist, and consultant in hematology at Mayo Clinic in Rochester, Minnesota, talks with Robert Negrin, MD, Professor of Medicine at Stanford University and president-elect of ASH. They discuss recent developments in reducing graft versus host disease in allogenic stem cell transplant. 

In this episode, Contributing Editor Samuel Wilson, MD, talks with Francis Couturaud, MD, PhD, Professor of Pulmonology at University of Brest in France. They discuss low-dose direct oral anticoagulants for extended venous thromboembolism prophylaxis.

In this episode, Contributing Editor, Lauren Pommert, MD, MS, leads a conversation with Karen Rabin, MD, PhD, pediatric oncologist at the University of California, San Francisco, and Hans Hitzler, MD, with SickKids Children's Hospital in Toronto. They discuss advances in understanding the disease biology of down syndrome associated acute leukemia. Support for this episode provided by Autolus.

In this episode, Contributing Editor Lori Muffly, MD, MS, leads a conversation with two patients — Matt and Rohan — both of whom have undergone cord blood transplants for their acute myeloid leukemia. They discuss the value of peer connection as a vital component of their leukemia and transplant journey.

In this episode, Contributing Editor Surbhi Shah, MBBS, MD, a clinician, researcher, and educator at Mayo Clinic in Phoenix, Arizona, talks with Keith McCrae, MD, director of classical hematology at the Taussig Cancer Institute and professor of molecular medicine at the Cleveland Clinic Lerner College of Medicine in Ohio. They discuss a recent paper co-authored by Dr. McCrae, “Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.” Support for this episode provided by Autolus.

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston. They discuss a phase I study with recent results that point to a potentially significant advance in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-term follow-up of the STOPAGO study, which focuses on the use of thrombopoietin receptor agonists on patients with immune thrombocytopenia. Support for this episode provided by Autolus.

In this episode, Contributing Editor Samuel Wilson, MD, MSCR, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Excellence. They talk about a systematic literature review, led by Dr. DeBaun and published in the journal Blood, that found no link between sickle cell trait and sudden death – a finding that challenges a long-standing myth about the trait. Support for this episode provide by Siemens Healthineers.

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School. They talk about the use of Glofit-GemOx in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Support for this episode provided by Autolus.

In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine at Stanford University where she focuses on cellular therapy for adults with acute leukemia, talks with Steven Devine, MD, the chief medical officer at the National Marrow Donor Program. They talk about the rise of HLA-mismatched unrelated donor transplants in the U.S.